FDA and Roxane Laboratories are warning of serious adverse events and deaths as a result of a mistake in dosage of morphine sulfate oral solutions.
FDA and Roxane Laboratories are warning of serious adverse events and deaths as a result of a mistake in dosage of morphine sulfate oral solutions.
In most of the cases, morphine sulfate oral solutions ordered in milligrams were mistakenly interchanged for milliliters. The result may be that a prescribed 5-mg dose is mistakenly administered as 5 mL, representing a 20-fold overdose. The risk of overdose is especially high when using the high-potency, 100 mg/5 mL product for relief of moderate to severe pain in opiod-tolerant patients, according to FDA.
Errors also may stem from a lack of understanding of the concentration of morphine in the oral solution, according to Columbus, Ohio-based Roxane Laboratories.
Roxane Laboratories has changed the packaging and labeling of the product. New packaging includes the warning, “Only For Use in Patients Who are Opioid Tolerant.” Another change is dose strength, which is now presented as 100 mg/5 mL, followed by 20 mg/mL less prominently displayed. The intent is to differentiate the product from the 20 mg/5 mL morphine sulfate product.
Before the change, the dose strength was expressed as 20 mg/mL, potentially leading to confusion.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More